Studies that are enrolling

A5354: Early ART in Acute HIV

ACTG A5354/EARLIER: Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses

Study Description
This study will include people who have very recently been infected with HIV and will start anti-HIV (antiretroviral) drugs right away to see how this may change HIV’s impact on the body. 

A5350: Effects of Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers

Safety, Tolerability and Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome and Immune Activation Markers in HIV-infected Participants on Suppressive Antiretroviral Therapy: A Phase II Study

A5341s: A5321 Sampling Substudy

A5341s: Longitudinal Sampling Substudy of A5321

Why is this substudy, A5341s, being done?

This substudy will compare samples from different reservoirs to learn more about the following:

A5332: Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)

Treatment Category

Treatment Experienced

Study Description

REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months. The trial is testing the effect of statin therapy on preventing heart disease and death in HIV-infected persons on HIV medications who do not meet guidelines for starting statins.      

A5320: Long-Term HCV

Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)

Study Description

A5320 (also known as the V-HICS study) is an observational, prospective, long-term follow-up study for men and women who have hepatitis C virus (HCV) infection alone (mono-infected) or who have both HCV and HIV-1 infection (co-infected).  Persons who were treated with a direct-acting anti-viral (DAA) therapy as a component of their hepatitis C treatment regimen in a clinical trial are eligible.

Treatment Category


A5315: Romidepsin to awaken HIV

A Phase I/II Study of Single Dose Romidepsin in HIV-infected Adults with Suppressed Viremia on Antiretroviral Therapy to Assess Safety, Tolerability, and Activation of HIV-1 Expression

A5312: High-Dose Isoniazid

A5312: The Early Bactericidal Activity of High Dose or Standard Dose Isoniazid among Adult Participants with Isoniazid-Resistant or Drug Sensitive Tuberculosis

A5243: Non-US Genomic Sampling

Plan for Obtaining Human Biological Samples at Non-U.S. Clinical Research Sites for Currently Unspecified Genetic Analyses

Study Description

This is a study to collect blood and saliva samples from former and current participants in AIDS Clinical Trial Group (ACTG) studies at non-U.S. sites.

Why is this study being done?

All samples will be stored for future HIV-related genetic testing. Any use of these samples will have to be approved both by the ACTG and by site Ethics Committees.

A5128: US Genomic Sampling

Plan for Obtaining Informed Consent to use Stored Human Biological Materials (HBM) for Currently Unspecified Analysis.

Study Description

Informed consent to use stored specimens for currently unspecified/ genetic analyses.

Why is this study being done?

To develop a standard operating procedure to establish a storage bank for specimens for future genetic (DNA) analyses.

Who can join?

Anyone enrolled in an ACTG study.

What do I need to do in the study?

Blood stored for future testing.

Subscribe to RSS - Enrolling